ROIV insider transaction filings
Roivant Sciences Ltd. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen ROIV transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 33 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 38 legs across 14 filings by 7 insiders — 7,172,289 shares, $248,709,736 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 54.
- Largest priced transaction: sale of 600,000 shares @ $34.59 ($20,754,000) by Gold Daniel Allen, filed 2026-06-30.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Sukhatme Mayukh — President & CIO, Director | 4 | — | 9 legs · 2,000,000 sh · $70,626,215 | 18 |
| MANCHESTER KEITH S — Director | 2 | — | 6 legs · 1,638,163 sh · $56,444,076 | 2 |
| Gold Daniel Allen — Director | 3 | — | 5 legs · 1,438,163 sh · $49,354,076 | 3 |
| QVT Financial LP | 1 | — | 5 legs · 1,438,163 sh · $49,354,076 | — |
| Venker Eric — President & Immunovant CEO | 4 | — | 5 legs · 600,000 sh · $20,774,660 | 7 |
| Fitzgerald Meghan — Director | 5 | — | 4 legs · 35,112 sh · $1,350,152 | 7 |
| Epperly Melissa B, — Director | 5 | — | 4 legs · 22,688 sh · $806,481 | 6 |
| MOMTAZEE JAMES C — Director | 3 | — | — | 4 |
| Oren Ilan — Director | 3 | — | — | 4 |
| Gline Matthew — CEO, Director | 1 | — | — | 1 |
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Roivant Sciences Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | MANCHESTER KEITH S — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Gold Daniel Allen — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Oren Ilan — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Epperly Melissa B, — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Fitzgerald Meghan — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Epperly Melissa B, — Director | Sale (S): 4,338 @ $39.65 · Sale (S): 600 @ $40.38 | EDGAR |
| 2026-09-17 | 4 | Fitzgerald Meghan — Director | Sale (S): 4,712 @ $39.68 · Sale (S): 400 @ $40.45 | EDGAR |
| 2026-09-14 | 4 | Gold Daniel Allen — Director | Tax withholding (F): 5,133 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Oren Ilan — Director | Tax withholding (F): 2,378 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Epperly Melissa B, — Director | Tax withholding (F): 2,179 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Fitzgerald Meghan — Director | Tax withholding (F): 1,743 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | MOMTAZEE JAMES C — Director | Tax withholding (F): 2,905 @ $40.94 | EDGAR |
| 2026-09-10 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 20,000 @ $8.80 · Sale (S): 20,000 @ $39.90 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 166,182 @ $35.63 · Sale (S): 33,818 @ $36.44 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | Pulik Richard — CFO | Tax withholding (F): 5,749 @ $36.84 | EDGAR |
| 2026-08-24 | 4 | Venker Eric — President & Immunovant CEO | Tax withholding (F): 13,909 @ $36.84 | EDGAR |
| 2026-08-21 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 172,899 @ $3.85 · Sale (S): 172,899 @ $37.17 · Option exercise (M): 17,519 @ $3.85 · Sale (S): 17,519 @ $37.30 · Option exercise (M): 144,756 @ $3.85 · Sale (S): 144,756 @ $36.48 · +3 more | EDGAR |
| 2026-08-18 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 243,177 @ $3.85 · Sale (S): 243,177 @ $36.23 · Option exercise (M): 284,707 @ $3.85 · Sale (S): 284,707 @ $36.25 · Option exercise (M): 105,141 @ $3.85 · Sale (S): 105,141 @ $36.59 · +5 more | EDGAR |
| 2026-07-29 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $34.95 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Epperly Melissa B, — Director | Grant/award (A): 543 @ $0 | EDGAR |
| 2026-07-21 | 4 | Oren Ilan — Director | Grant/award (A): 775 @ $0 | EDGAR |
| 2026-07-21 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 405 @ $0 | EDGAR |
| 2026-07-02 | 4 | Gline Matthew — CEO, Director | Tax withholding (F): 76,171 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 40,310 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Sukhatme Mayukh — President & CIO, Director | Tax withholding (F): 46,878 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 10,000 @ $8.80 · Sale (S): 10,000 @ $34.90 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Epperly Melissa B, — Director | Option exercise (M): 17,750 @ $4.46 · Sale (S): 15,002 @ $34.32 · Sale (S): 2,748 @ $34.71 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Gold Daniel Allen — Director | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 | EDGAR |
| 2026-06-30 | 4 | QVT Financial LP | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 | EDGAR |
| 2026-06-30 | 4 | MANCHESTER KEITH S — Director | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 · Sale (S): 200,000 @ $35.45 | EDGAR |
| 2026-06-29 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 500,000 @ $3.85 · Sale (S): 500,000 @ $34.13 · Option exercise (M): 500,000 @ $3.85 · Sale (S): 500,000 @ $34.08 · Option exercise (M): 500,000 (derivative) @ $0 · Option exercise (M): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 153,766 @ $33.05 · Sale (S): 46,234 @ $33.51 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Pulik Richard — CFO | Tax withholding (F): 2,129 @ $31.43 | EDGAR |
| 2026-06-23 | 4 | Humes Jennifer — Chief Accounting Officer | Tax withholding (F): 3,582 @ $31.43 | EDGAR |
| 2026-05-22 | 4 | Venker Eric — President & Immunovant CEO | Tax withholding (F): 34,483 @ $32.41 · Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $30.27 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Pulik Richard — CFO | Tax withholding (F): 18,962 @ $32.41 | EDGAR |
| 2026-04-22 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $29.59 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Pulik Richard — CFO | Grant/award (A): 60,644 @ $0 · Grant/award (A): 84,026 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Humes Jennifer — Chief Accounting Officer | Grant/award (A): 29,173 @ $0 · Grant/award (A): 27,157 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Epperly Melissa B, — Director | Grant/award (A): 670 @ $0 | EDGAR |
| 2026-04-21 | 4 | Oren Ilan — Director | Grant/award (A): 896 @ $0 · Tax withholding (F): 95 @ $29.83 | EDGAR |
| 2026-04-21 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 469 @ $0 · Tax withholding (F): 94 @ $29.83 | EDGAR |
| 2026-04-20 | 4 | Gline Matthew — CEO, Director | Sale (S): 289,774 @ $29.16 | EDGAR |
| 2026-04-10 | 4 | Humes Jennifer — Chief Accounting Officer | Sale (S): 13,538 @ $28.37 | EDGAR |
| 2026-04-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 160,035 @ $27.70 | EDGAR |
| 2026-04-01 | 4 | Gline Matthew — CEO, Director | Option exercise (M): 97,319 · Tax withholding (F): 53,826 @ $26.41 · Tax withholding (F): 304,684 @ $27.70 · Option exercise (M): 2,178,150 (derivative) @ $11.50 | EDGAR |
| 2026-04-01 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 58,391 · Tax withholding (F): 29,809 @ $26.41 · Tax withholding (F): 187,512 @ $27.70 · Option exercise (M): 1,306,889 (derivative) @ $11.50 | EDGAR |
| 2026-03-30 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 70,000 @ $8.80 · Sale (S): 70,000 @ $27.45 · Option exercise (M): 70,000 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Humes Jennifer — Chief Accounting Officer | Tax withholding (F): 14,526 @ $27.70 | EDGAR |
Recent 8-K events — Roivant Sciences Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ROIV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →